Wockhardt sees Q2 revenue surge, driven by antibiotic innovation and biosimilar expansion
Wockhardt Limited, a leading pharmaceutical and biotechnology company, released its second-quarter financial results for the fiscal year 2024-25, showing significant growth across several critical areas. ... Read More
FDA grants FELIQS fast track status for FLQ-101 in ROP preventive treatment
FELIQS, a multinational clinical-stage biopharmaceutical firm headquartered in Japan, has announced that its leading asset, FLQ-101, has received Fast Track designation from the U.S. Food ... Read More
Orthocell secures key regulatory approval for Remplir in Singapore, paving way for ASEAN expansion
Orthocell, an Australian regenerative medicine company, has achieved a significant milestone with the receipt of major international regulatory approval for its nerve repair product Remplir ... Read More
Miracle cure: Wockhardt’s experimental drug defeats deadly superbug in dramatic recovery
Wockhardt Limited announced that its investigational drug Zaynich (Zidebactam/Cefepime) has successfully treated a complex case of bacterial meningitis caused by a pan-drug-resistant superbug under compassionate ... Read More
Galderma’s breakthrough drug Nemluvio gains rapid FDA approval for severe itch condition
Galderma has achieved a significant milestone with the U.S. Food and Drug Administration (FDA) approving Nemluvio (nemolizumab) for the treatment of prurigo nodularis in adults. ... Read More
Lupin Limited sees explosive profit surge in Q1 FY2025
Lupin Limited has reported a remarkable financial performance for the quarter ending June 30, 2024. The pharmaceutical giant's sales for Q1 FY2025 reached INR 55,143 ... Read More
Lupin Limited secures major victory: A perfect FDA score for its Gujarat plant
Lupin Limited (Lupin), a global pharmaceutical powerhouse, has been awarded the Establishment Inspection Report (EIR) by the United States Food and Drug Administration (U.S. FDA). ... Read More